# US 11,738,078 B2 · Severe fever with thrombocytopenia syndrome virus > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,738,078 B2 - Document ID: US11738078B2 - Status: Granted - Kind: B2 - Application number: 17/050,602 - Filed: 2019-04-23 - Published: 2021-04-29 - Granted: 2023-08-29 - Earliest claimed: 2018-04-25 - Assignees: I.D.Bio. - Applicants: I.D.Bio. - Inventors: Yeo-Jeong Choi; Su-Jin Park; Young-Il Kim; Min-Ah Yu - Web page: https://patentgrep.com/patent/US11738078B2 ## CPC - A61K 39/12: Viral antigens - A61P 31/12: Antivirals - A61P 31/14: for RNA viruses - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - G01N 33/569: for microorganisms, e.g. protozoa, bacteria, viruses - G01N 33/56983: {Viruses} - A61K 2039/5252: {inactivated (killed)} - A61K 2039/575: {humoral response} - A61K 2039/6056: {Antibodies} - C12N 2760/12034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - C12N 2760/12234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - G01N 2333/175: Bunyaviridae, e.g. California encephalitis virus, Rift valley fever virus, Hantaan virus - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The present invention relates to a novel genotype of severe fever with thrombocytopenia syndrome viruses and use thereof as an immunogenic composition. The severe fever with thrombocytopenia syndrome viruses of the present invention are genetically different from conventional severe fever with thrombocytopenia syndrome viruses and are novel viruses taxonomically belonging to three sub-groups of genotype B. In view of the vaccine property that specific genotype viruses alone show only limited protective potential, the novel viruses of the present invention may be advantageously used as a vaccine having excellent cross-immunogenicity for SFTSV. ## Claims ### Claim 1 An immunogenic composition for prevention or treatment of a severe fever with thrombocytopenia syndrome, comprising inactivated severe fever with thrombocytopenia syndrome virus or a gene thereof as an active ingredient, and an adjuvant, wherein the severe fever with thrombocytopenia syndrome virus or the gene thereof comprises: (i) a L gene that encodes a protein having the sequence of SEQ ID NO: 17, and a M gene that encodes a protein having the sequence of SEQ ID NO: 18, or (iii) a L gene that encodes a protein having the sequence of SEQ ID NO: 21, and a M gene that encodes a protein having the sequence of SEQ ID NO: 22. ### Claim 2 (depends on 1) The composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier. ### Claim 3 (depends on 1) The composition of claim 1, wherein the immunogenic composition contains, as an active ingredient: a severe fever with thrombocytopenia syndrome virus containing an L gene containing a base sequence represented by SEQ ID NO: 5, an M gene containing a base sequence represented by SEQ ID NO: 6, an NP gene containing a base sequence represented by SEQ ID NO: 7, and an NS gene containing a base sequence represented by SEQ ID NO: 8; or a severe fever with thrombocytopenia syndrome virus containing an L gene containing a base sequence represented by SEQ ID NO: 9, an M gene containing a base sequence represented by SEQ ID NO: 10, an NP gene containing a base sequence represented by SEQ ID NO: 11, and an NS gene containing a base sequence represented by SEQ ID NO: 12. ### Claim 4 A method for detecting a severe fever with thrombocytopenia syndrome virus antibody, the method comprising: (a) contacting a sample isolated from a specimen with severe fever with thrombocytopenia syndrome virus or a gene thereof under a condition in which an antigen-antibody complex is able to be formed; and (b) detecting the formation of the antigen-antibody complex, wherein the severe fever with thrombocytopenia syndrome virus, or the gene thereof comprises (i) a L gene that encodes a protein having the sequence of SEQ ID NO: 17, and a M gene that encodes a protein having the sequence of SEQ ID NO: 18, or (iii) a L gene that encodes a protein having the sequence of SEQ ID NO: 21, and a M gene that encodes a protein having the sequence of SEQ ID NO: 22. ### Claim 5 A method for producing antiserum against a severe fever with thrombocytopenia syndrome virus in a non-human animal, the method comprising: (a) administering severe fever with thrombocytopenia syndrome virus or a gene thereof to the non-human animal at an amount effective to induce an immune response; and (b) collecting antiserum or plasma containing an antibody against the severe fever with thrombocytopenia syndrome virus, wherein the severe fever with thrombocytopenia syndrome virus or the gene thereof comprises (i) a L gene that encodes a protein having the sequence of SEQ ID NO: 17, and a M gene that encodes a protein having the sequence of SEQ ID NO: 18, or (iii) a L gene that encodes a protein having the sequence of SEQ ID NO: 21, and a M gene that encodes a protein having the sequence of SEQ ID NO: 22.